Does the media refer more to TMO or ANGO?

In the previous week, Thermo Fisher Scientific had 18 more articles in the media than AngioDynamics. MarketBeat recorded 21 mentions for Thermo Fisher Scientific and 3 mentions for AngioDynamics. Thermo Fisher Scientific's average media sentiment score of 1.10 beat AngioDynamics' score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Thermo Fisher Scientific 14 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AngioDynamics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer WST or ANGO?

In the previous week, West Pharmaceutical Services had 13 more articles in the media than AngioDynamics. MarketBeat recorded 16 mentions for West Pharmaceutical Services and 3 mentions for AngioDynamics. West Pharmaceutical Services' average media sentiment score of 0.85 beat AngioDynamics' score of 0.00 indicating that West Pharmaceutical Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment West Pharmaceutical Services 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AngioDynamics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NVCR or ANGO more profitable?

AngioDynamics has a net margin of -11.48% compared to NovoCure's net margin of -21.25%. AngioDynamics' return on equity of -5.73% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% AngioDynamics -11.48% -5.73% -3.77%

Does the media prefer NVCR or ANGO?

In the previous week, NovoCure had 1 more articles in the media than AngioDynamics. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for AngioDynamics. NovoCure's average media sentiment score of 0.20 beat AngioDynamics' score of 0.00 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral AngioDynamics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BFLY or ANGO?

In the previous week, Butterfly Network had 3 more articles in the media than AngioDynamics. MarketBeat recorded 6 mentions for Butterfly Network and 3 mentions for AngioDynamics. Butterfly Network's average media sentiment score of 0.44 beat AngioDynamics' score of 0.00 indicating that Butterfly Network is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AngioDynamics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

AngioDynamics (ANGO) Competitors

$15.44 +0.07 (+0.46%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$15.44 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Compare

ANGO vs. TMO, WST, ESTA, NVCR, and BFLY

Should you buy AngioDynamics stock or one of its competitors? AngioDynamics's main competitors and comparable companies include Thermo Fisher Scientific (TMO), West Pharmaceutical Services (WST), Establishment Labs (ESTA), NovoCure (NVCR), and Butterfly Network (BFLY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does AngioDynamics compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and AngioDynamics (NASDAQ:ANGO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Thermo Fisher Scientific has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

Thermo Fisher Scientific has a net margin of 15.04% compared to AngioDynamics' net margin of -11.48%. Thermo Fisher Scientific's return on equity of 17.09% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.04%	17.09%	8.12%
AngioDynamics	-11.48%	-5.73%	-3.77%

In the previous week, Thermo Fisher Scientific had 18 more articles in the media than AngioDynamics. MarketBeat recorded 21 mentions for Thermo Fisher Scientific and 3 mentions for AngioDynamics. Thermo Fisher Scientific's average media sentiment score of 1.10 beat AngioDynamics' score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Thermo Fisher Scientific	14 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AngioDynamics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 89.4% of AngioDynamics shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 6.0% of AngioDynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Thermo Fisher Scientific has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$44.56B	5.40	$6.70B	$18.59	35.01
AngioDynamics	$320.17M	1.99	-$36.74M	-$0.87	N/A

Thermo Fisher Scientific presently has a consensus price target of $624.64, indicating a potential downside of 4.02%. AngioDynamics has a consensus price target of $19.50, indicating a potential upside of 26.30%. Given AngioDynamics' higher probable upside, analysts clearly believe AngioDynamics is more favorable than Thermo Fisher Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	2 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.73
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Thermo Fisher Scientific beats AngioDynamics on 14 of the 17 factors compared between the two stocks.

How does AngioDynamics compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and AngioDynamics (NASDAQ:ANGO) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

West Pharmaceutical Services has a net margin of 16.98% compared to AngioDynamics' net margin of -11.48%. West Pharmaceutical Services' return on equity of 20.11% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	16.98%	20.11%	14.83%
AngioDynamics	-11.48%	-5.73%	-3.77%

In the previous week, West Pharmaceutical Services had 13 more articles in the media than AngioDynamics. MarketBeat recorded 16 mentions for West Pharmaceutical Services and 3 mentions for AngioDynamics. West Pharmaceutical Services' average media sentiment score of 0.85 beat AngioDynamics' score of 0.00 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
West Pharmaceutical Services	11 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AngioDynamics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

West Pharmaceutical Services has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

West Pharmaceutical Services presently has a consensus price target of $379.08, suggesting a potential upside of 4.77%. AngioDynamics has a consensus price target of $19.50, suggesting a potential upside of 26.30%. Given AngioDynamics' higher probable upside, analysts clearly believe AngioDynamics is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 6.0% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

West Pharmaceutical Services has higher revenue and earnings than AngioDynamics. AngioDynamics is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.07B	8.28	$493.70M	$7.81	46.33
AngioDynamics	$320.17M	1.99	-$36.74M	-$0.87	N/A

Summary

West Pharmaceutical Services beats AngioDynamics on 14 of the 17 factors compared between the two stocks.

How does AngioDynamics compare to Establishment Labs?

AngioDynamics (NASDAQ:ANGO) and Establishment Labs (NASDAQ:ESTA) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

AngioDynamics currently has a consensus price target of $19.50, suggesting a potential upside of 26.30%. Establishment Labs has a consensus price target of $100.25, suggesting a potential upside of 44.66%. Given Establishment Labs' stronger consensus rating and higher probable upside, analysts clearly believe Establishment Labs is more favorable than AngioDynamics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 72.9% of Establishment Labs shares are held by institutional investors. 6.0% of AngioDynamics shares are held by insiders. Comparatively, 10.0% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AngioDynamics has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

AngioDynamics has a net margin of -11.48% compared to Establishment Labs' net margin of -15.82%. AngioDynamics' return on equity of -5.73% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AngioDynamics	-11.48%	-5.73%	-3.77%
Establishment Labs	-15.82%	-196.69%	-10.73%

In the previous week, AngioDynamics had 3 more articles in the media than Establishment Labs. MarketBeat recorded 3 mentions for AngioDynamics and 0 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.67 beat AngioDynamics' score of 0.00 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
AngioDynamics	Neutral
Establishment Labs	Very Positive

AngioDynamics has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioDynamics	$320.17M	1.99	-$36.74M	-$0.87	N/A
Establishment Labs	$211.08M	9.78	-$51.06M	-$1.31	N/A

Summary

AngioDynamics beats Establishment Labs on 10 of the 17 factors compared between the two stocks.

How does AngioDynamics compare to NovoCure?

NovoCure (NASDAQ:NVCR) and AngioDynamics (NASDAQ:ANGO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

NovoCure has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

AngioDynamics has lower revenue, but higher earnings than NovoCure. AngioDynamics is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.97	-$136.23M	-$1.30	N/A
AngioDynamics	$320.17M	1.99	-$36.74M	-$0.87	N/A

84.6% of NovoCure shares are held by institutional investors. Comparatively, 89.4% of AngioDynamics shares are held by institutional investors. 6.6% of NovoCure shares are held by company insiders. Comparatively, 6.0% of AngioDynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, NovoCure had 1 more articles in the media than AngioDynamics. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for AngioDynamics. NovoCure's average media sentiment score of 0.20 beat AngioDynamics' score of 0.00 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
AngioDynamics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AngioDynamics has a net margin of -11.48% compared to NovoCure's net margin of -21.25%. AngioDynamics' return on equity of -5.73% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
AngioDynamics	-11.48%	-5.73%	-3.77%

NovoCure currently has a consensus target price of $21.20, suggesting a potential upside of 27.02%. AngioDynamics has a consensus target price of $19.50, suggesting a potential upside of 26.30%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than AngioDynamics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

NovoCure and AngioDynamics tied by winning 8 of the 16 factors compared between the two stocks.

How does AngioDynamics compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and AngioDynamics (NASDAQ:ANGO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

37.9% of Butterfly Network shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by company insiders. Comparatively, 6.0% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

AngioDynamics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	21.54	-$77.06M	-$0.29	N/A
AngioDynamics	$320.17M	1.99	-$36.74M	-$0.87	N/A

Butterfly Network currently has a consensus target price of $6.56, suggesting a potential downside of 16.87%. AngioDynamics has a consensus target price of $19.50, suggesting a potential upside of 26.30%. Given AngioDynamics' higher probable upside, analysts plainly believe AngioDynamics is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
AngioDynamics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Butterfly Network had 3 more articles in the media than AngioDynamics. MarketBeat recorded 6 mentions for Butterfly Network and 3 mentions for AngioDynamics. Butterfly Network's average media sentiment score of 0.44 beat AngioDynamics' score of 0.00 indicating that Butterfly Network is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AngioDynamics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AngioDynamics has a net margin of -11.48% compared to Butterfly Network's net margin of -66.74%. AngioDynamics' return on equity of -5.73% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-66.74%	-33.99%	-22.96%
AngioDynamics	-11.48%	-5.73%	-3.77%

Butterfly Network has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, AngioDynamics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

Summary

AngioDynamics beats Butterfly Network on 9 of the 16 factors compared between the two stocks.

Get AngioDynamics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANGO vs. The Competition

Export

Metric	AngioDynamics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$638.17M	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	-17.75	25.34	275.49	25.40
Price / Sales	1.99	72.49	646.01	89.45
Price / Cash	49.35	32.64	76.25	51.42
Price / Book	3.74	5.69	10.46	6.33
Net Income	-$36.74M	$151.55M	$3.49B	$358.33M
7 Day Performance	1.11%	0.66%	0.59%	1.12%
1 Month Performance	-2.40%	-3.33%	-1.74%	-2.39%
1 Year Performance	43.36%	6.79%	18.13%	5.35%

AngioDynamics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANGO AngioDynamics	2.4305 of 5 stars	$15.44 +0.5%	$19.50 +26.3%	+43.4%	$638.17M	$320.17M	N/A	632	News Coverage High Trading Volume
TMO Thermo Fisher Scientific	3.7769 of 5 stars	$605.02 -1.4%	$619.41 +2.4%	+35.6%	$223.44B	$44.56B	32.51	125,000	Positive News Ex-Dividend
WST West Pharmaceutical Services	3.2395 of 5 stars	$335.40 -1.3%	$368.08 +9.7%	+42.1%	$23.65B	$3.07B	43.02	10,800	Insider Trade
ESTA Establishment Labs	2.8702 of 5 stars	$74.68 +0.5%	$100.25 +34.2%	+75.6%	$2.23B	$211.08M	N/A	1,004
NVCR NovoCure	2.4026 of 5 stars	$17.42 -2.9%	$21.20 +21.7%	+31.5%	$2.03B	$655.35M	N/A	1,605	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANGO) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AngioDynamics (ANGO) Competitors

ANGO vs. TMO, WST, ESTA, NVCR, and BFLY

How does AngioDynamics compare to Thermo Fisher Scientific?

Summary

How does AngioDynamics compare to West Pharmaceutical Services?

Summary

How does AngioDynamics compare to Establishment Labs?

Summary

How does AngioDynamics compare to NovoCure?

Summary

How does AngioDynamics compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANGO vs. The Competition

AngioDynamics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AngioDynamics (ANGO) Competitors

ANGO vs. TMO, WST, ESTA, NVCR, and BFLY

How does AngioDynamics compare to Thermo Fisher Scientific?

Which has more risk and volatility, TMO or ANGO?

Is TMO or ANGO more profitable?

Does the media refer more to TMO or ANGO?

Do insiders & institutionals believe in TMO or ANGO?

Which has better valuation and earnings, TMO or ANGO?

Do analysts prefer TMO or ANGO?

Summary

How does AngioDynamics compare to West Pharmaceutical Services?

Is WST or ANGO more profitable?

Does the media prefer WST or ANGO?

Which has more risk & volatility, WST or ANGO?

Do analysts prefer WST or ANGO?

Do institutionals & insiders have more ownership in WST or ANGO?

Which has higher valuation and earnings, WST or ANGO?

Summary

How does AngioDynamics compare to Establishment Labs?

Do analysts prefer ANGO or ESTA?

Do insiders and institutionals have more ownership in ANGO or ESTA?

Which has more volatility and risk, ANGO or ESTA?

Is ANGO or ESTA more profitable?

Does the media prefer ANGO or ESTA?

Which has better valuation & earnings, ANGO or ESTA?

Summary

How does AngioDynamics compare to NovoCure?

Which has more volatility and risk, NVCR or ANGO?

Which has better earnings and valuation, NVCR or ANGO?

Do insiders & institutionals hold more shares of NVCR or ANGO?

Does the media prefer NVCR or ANGO?

Is NVCR or ANGO more profitable?

Do analysts recommend NVCR or ANGO?

Summary

How does AngioDynamics compare to Butterfly Network?

Do insiders and institutionals hold more shares of BFLY or ANGO?

Which has better valuation and earnings, BFLY or ANGO?

Do analysts recommend BFLY or ANGO?

Does the media favor BFLY or ANGO?

Is BFLY or ANGO more profitable?

Which has more volatility & risk, BFLY or ANGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANGO vs. The Competition

AngioDynamics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools